Stocktoria
Spyre Therapeutics, Inc. SYRE
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2016-04-07
Spyre Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $886,000 | $2.3M | $18.7M |
| R&D expense | — | — | — | $58.6M | $57.1M |
| Operating income | -$209.6M | -$208.6M | -$242.3M | -$84.8M | -$65.6M |
| Income tax | -$15,000 | $51,000 | -$26,000 | -$136,000 | $141,000 |
| Net income | -$155.2M | -$208.0M | -$338.8M | -$83.8M | -$65.8M |
| EPS (diluted) | — | — | $-49.12 | $-24.86 | $-25.02 |
| Operating cash flow | -$169.3M | -$157.4M | -$99.9M | -$80.1M | -$53.7M |
| Free cash flow | — | -$157.4M | -$99.9M | -$80.2M | -$54.3M |
| Cash & equivalents | $85.7M | $89.4M | $188.9M | $34.9M | $15.1M |
| Total assets | $777.8M | $608.5M | $341.9M | $71.1M | $109.9M |
| Total liabilities | $62.5M | $90.7M | $73.3M | $20.8M | $26.0M |
| Shareholders' equity | $715.2M | $517.8M | $184.0M | $50.3M | $83.9M |
Source: SEC EDGAR filings · CIK 0001636282 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.